We demonstrate a direct fabrication of PbS nanocube supercrystals without size-selection pretreatment on the building blocks. Electron microscopic and synchrotron small angle X-ray scattering analyses confirm that nanocubes pack through a tilted face-centered-cubic (fcc) arrangement, that is, face-to-face along the <110>(super) direction, resulting in a real packing efficiency of as high as ∼83%. This new type of superstructure consisting of nanocubes as building blocks, reported here for the first time, is considered the most stable surfactant-capped nanocube superstructure determined by far.

This materials-by-design approach combines nanocrystal assembly with pressure processing to drive the attachment and coalescence of PbS nanocubes along directed crystallographic dimensions to form a large 3D porous architecture. This quenchable and strained mesostructure holds the storage of large internal stress, which stabilizes the high-pressure PbS phase in atmospheric conditions. Nanocube fusion enhances the structural stability; the large surface area maintains the size-dependent properties.

Breast cancer is a major ongoing public health issue among women in both developing and developed countries. Significant progress has been made to improve the breast cancer treatment in the past decades. However, the current clinical approaches are invasive, of low specificity and can generate severe side effects. As a rapidly developing field, nanotechnology brings promising opportunities to human cancer diagnosis and treatment. The use of nanoparticulate-based platforms overcomes biological barriers and allows prolonged blood circulation time, simultaneous tumor targeting and enhanced accumulation of drugs in tumors. Currently available and clinically applicable innovative nanoparticulate-based systems for breast cancer nanotherapies are discussed in this review.

Using an in situ synchrotron X-ray diffraction technique, a pressure-induced phase transformation of PbTe nanocrystals with sizes of 13 and 5 nm up to ∼20 GPa was studied. Upon an increase of pressure, we observed that the 13 nm PbTe nanocrystals start a phase transformation from rocksalt structure to an intermediate orthorhombic structure and finally CsCl-type structure at 8 GPa, which is 2 GPa higher than that in bulk PbTe. In contrast, the 5 nm PbTe nanocrystals do not display the same type of transition with a further increased transition pressure as expected. Instead of orthorhombic or CsCl-type structure, the 5 nm PbTe nanocrystals turn to amorphous phase under a similar pressure (8 GPa). Upon a release of pressure, the 13 nm PbTe nanocrystals transform from high pressure CsCl-type structure directly to rocksalt structure, whereas the 5 nm PbTe nanocrystals remain their amorphous phase to ambient conditions. The structure stability of rocksalt-type PbTe shows a significant reversal of Hall-Petch effect. On the basis of such an observation with a critical size determination of ∼9 nm, PbTe nanocrystals appear as the first class of material that demonstrates a pressure-induced structural change from order to disorder. By sharing the insight of this reversed Hall-Petch effect with associated transition types, we tuned our experimental protocol and successfully synthesized a sample with "high-pressure metastable structure", amorphous phase at ambient pressure. This integrative study provides a feasible pathway to understand nucleation mechanism as a function of particle size and to explore novel materials with high-pressure metastable structure and unique properties under lab-accessible conditions.

Pancreatic ductal adenocarcinomas (PDACs) constitutively express the G-protein-coupled cholecystokinin B receptor (CCKBR). In this study, we identified DNA aptamers (APs) that bind to the CCKBR and describe their characterization and targeting efficacy. Using dual SELEX selection against “exposed” CCKBR peptides and CCKBR-expressing PDAC cells, a pool of DNA APs was identified. Further downselection was based on predicted structures and properties, and we selected eight APs for initial characterizations. The APs bound specifically to the CCKBR, and we showed not only that they did not stimulate proliferation of PDAC cell lines but rather inhibited their proliferation. We chose one AP, termed AP1153, for further binding and localization studies. We found that AP1153 did not activate CCKBR signaling pathways, and three-dimensional Confocal microscopy showed that AP1153 was internalized by PDAC cells in a receptor-mediated manner. AP1153 showed a binding affinity of 15 pM. Bioconjugation of AP1153 to the surface of fluorescent NPs greatly facilitated delivery of NPs to PDAC tumors in vivo. The selectivity of this AP-targeted NP delivery system holds promise for enhanced early detection of PDAC lesions as well as improved chemotherapeutic treatments for PDAC patients.